Quantcast

Latest Exelixis Inc. Stories

2014-07-17 16:26:09

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-03-24 12:25:44

Editor Note: For more information about this release, please scroll to bottom. LONDON, March 24, 2014 /PRNewswire/ -- On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2008-11-06 06:00:21

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to discover novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective. XL228 is a potent small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R) and SRC, which are protein kinases known to promote cancer cell survival, proliferation, and migration. XL228 also inhibits BCR-ABL, a protein kinase...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.